@article{EbenbeckRieserJungjohannetal.2022,
  author    = {Ebenbeck, Nikola and Rieser, Jakob and Jungjohann, Jana and Gebhardt, Markus},
  title     = {How the existence of special schools affects the placement of students with special needs in inclusive primary schools},
  series = {Journal of Research in Special Educational Needs},
  volume    = {22},
  journal   = {Journal of Research in Special Educational Needs},
  number    = {3},
  doi       = {10.1111/1471-3802.12565},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-287308},
  pages     = {274 -- 287},
  year      = {2022},
  abstract  = {Although inclusion is the declared goal, the transition from a system based on special schools to an inclusive school system has only been progressing very slowly in individual countries. In an evolving school system, the existing special schools keep struggling to justify their existence. This study investigates the regional distribution effects based on official school data and shows the influence of a pull effect on special schools as a distance effect of special schools affecting the placement of students. For this purpose, official school statistics including all students at special and regular schools in the years 2010, 2015 and 2020 (N = 11 280 040) are evaluated in a spatiotemporal comparison using Educational Data Mining. In a hierarchical regression model on school placement in inclusive schools, the distance between primary and special schools has the highest influence (β = 0.48) on the inclusion rate (i.e., the proportion of students with special needs who are educated in regular schools in relation to all students with disabilities), along with the size (β = -0.14) and the density of special schools in a district (β = -0.12). The effects differ according to the population density of the region and are stronger in large cities. When the proportion of students with and without SEN in regular schools is considered (support rate), the density of special schools has the greatest impact on school placement (ß = 43.44). Self-preservation of schools, traditional funding systems and regional differences between urban and rural areas are discussed as possible reasons.},
  language  = {en}
}
@article{HaistStegeLangetal.2022,
  author    = {Haist, Maximilian and Stege, Henner and Lang, Berenice Mareen and Tsochataridou, Aikaterini and Salzmann, Martin and Mohr, Peter and Schadendorf, Dirk and Ugurel, Selma and Placke, Jan-Malte and Weichenthal, Michael and Gutzmer, Ralf and Leiter, Ulrike and Kaatz, Martin and Haferkamp, Sebastian and Berking, Carola and Heppt, Markus and Tschechne, Barbara and Schummer, Patrick and Gebhardt, Christoffer and Grabbe, Stephan and Loquai, Carmen},
  title     = {Response to first-line treatment with immune-checkpoint inhibitors in patients with advanced cutaneous squamous cell carcinoma: a multicenter, retrospective analysis from the German ADOReg registry},
  series = {Cancers},
  volume    = {14},
  journal   = {Cancers},
  number    = {22},
  issn      = {2072-6694},
  doi       = {10.3390/cancers14225543},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-297506},
  year      = {2022},
  abstract  = {Cutaneous squamous cell carcinoma (cSCC) is a common malignancy of the skin and has an overall favorable outcome, except for patients with an advanced stage of the disease. The efficacy of checkpoint inhibitors (CPI) for advanced cSCC has been demonstrated in recent clinical studies, but data from real-world cohorts and trial-ineligible cSCC patients are limited. We retrospectively investigated patients with advanced cSCC who have been treated with CPI in a first-line setting at eight German skin cancer centers registered within the multicenter registry ADOReg. Clinical outcome parameters including response, progression-free (PFS) and overall survival (OS), time-to-next-treatment (TTNT), and toxicity were analyzed and have been stratified by the individual immune status. Among 39 evaluable patients, the tumor response rate (rwTRR) was 48.6\%, the median PFS was 29.0 months, and the median OS was not reached. In addition, 9 patients showed an impaired immune status due to immunosuppressive medication or hematological diseases. Our data demonstrated that CPI also evoked tumor responses among immunocompromised patients (rwTRR: 48.1 vs. 50.0\%), although these responses less often resulted in durable remissions. In line with this, the median PFS (11 vs. 40 months, p = 0.059), TTNT (12 months vs. NR, p = 0.016), and OS (29 months vs. NR, p < 0.001) were significantly shorter for this patient cohort. CPI therapy was well tolerated in both subcohorts with 15\% discontinuing therapy due to toxicity. Our real-world data show that first-line CPI therapy produced strong and durable responses among patients with advanced cSCC. Immunocompromised patients were less likely to achieve long-term benefit from anti-PD1 treatment, despite similar tumor response rates.},
  language  = {en}
}